COVID stocks spike as market volatility continues

Valuation swings for five biotechs at the center of the COVID-19 race

As the broader markets continue to tumble amidst the COVID-19 pandemic, several biotechs at the center of the race to develop countermasures have seen their valuations swing wildly since the crisis began to unfold in January.

Five companies in particular have seen some of the largest peaks and valleys as investors -- in particular retail investors -- frantically trade on seemingly every piece of COVID-19 news.

Figure: YTD percentage changes of COVID-19 stocks

Five biotech stocks have seen major gains on news of their COVID-19 programs, sending them up as much as 379% from the start of the year. While their

Read the full 987 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers